MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+precursors

DOI PDF 2 Citations
  • Allan J. Masterson
    From the Department of Medical Oncology, Division Immunotherapy, and the Department of Pathology, VU University Medical Center VUmc, Amsterdam, The Netherlands; and Numico Research BV, Wageningen, The Netherlands.
  • Claudia C. Sombroek
    From the Department of Medical Oncology, Division Immunotherapy, and the Department of Pathology, VU University Medical Center VUmc, Amsterdam, The Netherlands; and Numico Research BV, Wageningen, The Netherlands.
  • Tanja D. de Gruijl
    From the Department of Medical Oncology, Division Immunotherapy, and the Department of Pathology, VU University Medical Center VUmc, Amsterdam, The Netherlands; and Numico Research BV, Wageningen, The Netherlands.
  • Yvo M. F. Graus
    From the Department of Medical Oncology, Division Immunotherapy, and the Department of Pathology, VU University Medical Center VUmc, Amsterdam, The Netherlands; and Numico Research BV, Wageningen, The Netherlands.
  • Hans J. J. van der Vliet
    From the Department of Medical Oncology, Division Immunotherapy, and the Department of Pathology, VU University Medical Center VUmc, Amsterdam, The Netherlands; and Numico Research BV, Wageningen, The Netherlands.
  • Sinéad M. Lougheed
    From the Department of Medical Oncology, Division Immunotherapy, and the Department of Pathology, VU University Medical Center VUmc, Amsterdam, The Netherlands; and Numico Research BV, Wageningen, The Netherlands.
  • Alfons J. M. van den Eertwegh
    From the Department of Medical Oncology, Division Immunotherapy, and the Department of Pathology, VU University Medical Center VUmc, Amsterdam, The Netherlands; and Numico Research BV, Wageningen, The Netherlands.
  • Herbert M. Pinedo
    From the Department of Medical Oncology, Division Immunotherapy, and the Department of Pathology, VU University Medical Center VUmc, Amsterdam, The Netherlands; and Numico Research BV, Wageningen, The Netherlands.
  • Rik J. Scheper
    From the Department of Medical Oncology, Division Immunotherapy, and the Department of Pathology, VU University Medical Center VUmc, Amsterdam, The Netherlands; and Numico Research BV, Wageningen, The Netherlands.

Search this article

Description

<jats:title>Abstract</jats:title><jats:p>Many human myeloid leukemia–derived cell lines possess the ability to acquire a dendritic cell (DC) phenotype. However, cytokine responsiveness is generally poor, requiring direct manipulation of intracellular signaling mechanisms for differentiation. In contrast, the CD34+ human acute myeloid leukemia cell line MUTZ-3 responds to granulocyte macrophage– colony-stimulating factor (GM-CSF), interleukin 4 (IL-4), and tumor necrosis factor alpha (TNFα), cytokines known to be pivotal both in vivo and in vitro for DC generation from monocytes and CD34+ stem cells. In all respects, MUTZ-3 cells behave as the immortalized equivalent of CD34+ DC precursors. Upon stimulation with specific cytokine cocktails, they acquire a phenotype consistent with either interstitial- or Langerhans-like DCs and upon maturation (mDC), express CD83. MUTZ-3 DC display the full range of functional antigen processing and presentation pathways. These findings demonstrate the unique suitability of MUTZ-3 cells as an unlimited source of CD34+DC progenitors for the study of cytokine-induced DC differentiation.</jats:p>

Journal

  • Blood

    Blood 100 (2), 701-703, 2002-07-15

    American Society of Hematology

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top